Exelixis: 1 to Watch for 2012

By David Williamson | More Articles
December 30, 2011 | Comments (2)

The following video is part of our "Motley Fool Conversations" series in which health-care editor and analyst David Williamson and industrials editor and analyst Brendan Byrnes discuss topics across the investing world.

In today's edition, David and Brendan discuss popular biotech Exelixis. They review the two deals the company brokered in recent weeks and how they will impact Exelixis as it tries to advance cabozantinib in 2012.

Looking for our prediction for 2012? Check out The Motley Fool's brand-new report, "The Motley Fool's Top Stock for 2012." It highlights a company that is revolutionizing commerce in Latin America. You can get instant access to the name of this company by clicking here -- it's free.

The Steve Jobs Betrayal
You may already know that in the final year of his life, Jobs revealed a stunning betrayal — and told his biographer, "I will spend my last dying breath... and every penny of Apple's $40 billion in the bank to right this wrong." What was it that made Jobs so irate — and why could it make a few in-the-know investors some major profits over the coming months and years?

Enter your email address below to find out what made Jobs so enraged!

Brendan Byrnes does not own shares of the companies listed above. David Williamson owns shares of Johnson & Johnson. The Motley Fool owns shares of Exelixis and Johnson & Johnson. Motley Fool newsletter services recommend Exelixis and Gilead Sciences. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Read/Post Comments (2) | Recommend This Article (3)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment icon found on every comment.

Report this Comment On December 31, 2011, at 3:20 PM, hiddenflem wrote:

Lesson: Never wear stripes when you are being videotaped.
Report this Comment On December 31, 2011, at 4:01 PM, portefeuille wrote:

some information on their competitor (in the field of bone metastases drugs) Algeta is here.
http://caps.fool.com/Blogs/european-biopharmaceuticals/68534...

Add your comment.

Compare Brokers

Fool Disclosure

DocumentId: 1750850, ~/Articles/ArticleHandler.aspx, 5/27/2012 2:02:16 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 1 day ago Sponsored by:
	DOW	12,454.83	-74.92	-0.60%
	S&P 500	1,317.82	-2.86	-0.22%
	NASD	2,837.53	-1.85	-0.07%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes